NCT04331808View on ClinicalTrials.gov

CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)

PHASE2CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

March 30, 2020

Primary Completion Date

May 4, 2020

Study Completion Date

November 9, 2020

Conditions
Corona Virus Infection
Interventions
DRUG

Tocilizumab

Tocilizumab 8mg/kg on day 1 and if no response (no decrease of oxygen requirement) a second injection at day 3 (fixed dose of 400 mg)

Trial Locations (8)

75012

APHP- Hopital Tenon, Paris

Unknown

APHP - Beaujon, Paris

APHP - Bichat, Paris

APHP - Hopital Necker, Paris

APHP - Pitié Salpêtrière, Paris

APHP - Saint Louis, Paris

CHU Strasbourg, Strasbourg

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04331808 - CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI) | Biotech Hunter | Biotech Hunter